| Insider-Aktien | 666.731 shares |
| Insider gesamt | 22 |
Insider-Stimmungswert
Der Insider-Stimmungswert ermittelt die Unternehmen, die von Unternehmensinsidern gekauft werden.
Es ist das Ergebnis eines ausgeklügelten quantitativen Multifaktormodells, das die Unternehmen mit der höchsten Insiderakkumulation identifiziert. Das Scoring-Modell verwendet eine Kombination aus der Nettozahl der Insiderkäufe der letzten 90 Tage, der Gesamtzahl der gekauften Aktien als Prozentsatz des Streubesitzes und der Gesamtzahl der von Insidern gehaltenen Aktien. Die Zahl reicht von 0 bis 100, wobei höhere Zahlen ein höheres Maß an Insiderkäufen anzeigen als bei anderen Unternehmen und 50 den Durchschnitt darstellt.
Aktualisierungshäufigkeit: Täglich
Führungskräfte-Stimmungswert
Der Führungskräfte-Stimmungswert findet Unternehmen, die von Führungskräften des Unternehmens gekauft werden.
Per Definition sind Führungskräfte des Unternehmens Insider, aber im Gegensatz zu anderen Insidern (10%ige Aktionäre und Vorstandsmitglieder) arbeiten Führungskräfte täglich für das Unternehmen und verwenden beim Handel ihr eigenes Geld. (10%ige Aktionäre und Vorstandsmitglieder sind oft Fondsmanager, die das Geld anderer Leute verwalten.) Daher sind Insider-Geschäfte, die von Führungskräften getätigt werden, viel bedeutender und sollten entsprechend behandelt werden.
Wie der Insider-Stimmungswert ist auch der Führungskräfte-Stimmungswert das Ergebnis eines ausgeklügelten quantitativen Multifaktormodells, das die Unternehmen mit der höchsten Führungskräftekonzentration identifiziert.
Aktualisierungshäufigkeit: Täglich
Wichtige Insider-Kennzahlen
Diese Karte zeigt, wie das Unternehmen bei verschiedenen Insider-Kennzahlen abschneidet. Der Perzentil-Rang zeigt, wie dieses Unternehmen im Vergleich zu anderen Unternehmen auf den US-Märkten abschneidet. Höhere Ränge deuten auf eine bessere Situation hin.
Es ist beispielsweise allgemein anerkannt, dass Insiderkäufe ein positiver Indikator sind, so dass Unternehmen mit mehr Insiderkäufen besser abschneiden würden als Unternehmen mit weniger Insiderkäufen (oder sogar Insiderverkäufen).
Prozent des Streubesitzes von Insidern gekauft (Rang)
N/A
Prozent des von Insidern gekauften Streubesitzes ist die Gesamtzahl der von Insidern gekauften Aktien abzüglich der Gesamtzahl der von Insidern in den letzten 90 Tagen verkauften Aktien, geteilt durch den gesamten Streubesitz und multipliziert mit 100.
Diagramm zum Insiderhandel
Sensei Biotherapeutics, Inc. Insider-Trades sind in der folgenden Grafik dargestellt. Insider sind leitende Angestellte, Direktoren oder bedeutende Investoren in einem Unternehmen. Im Allgemeinen ist es für Insider illegal, auf der Grundlage von wesentlichen, nicht-öffentlichen Informationen mit Aktien ihrer Unternehmen zu handeln. Das bedeutet nicht, dass es für sie illegal ist, irgendwelche Geschäfte in ihren eigenen Unternehmen zu tätigen. Sie müssen jedoch alle Geschäfte der SEC über ein Formular 4 melden.
Kennzahlen zu Insiderlisten und Rentabilität
Diese Tabelle zeigt die Liste der bekannten Insider und wird automatisch aus den bei der SEC eingereichten Unterlagen erstellt. Zusätzlich zu den Namen, dem letzten Titel und der Bezeichnung als Direktor, leitender Angestellter oder 10%-iger Anteilseigner geben wir die zuletzt veröffentlichten Bestände an. Zusätzlich stellen wir, wenn möglich, die historische Handelsperformance für den Insider zur Verfügung. Die historische Handelsperformance ist ein gewichteter Durchschnitt der Performance tatsächlicher offener Kauftransaktionen, die von dem Insider getätigt wurden. Weitere Informationen zur Berechnung dieses Wertes finden Sie in diesem YouTube-Webinar.
See our leaderboard of most profitable insider traders.
| Insider | Durchschnittlicher Gewinn (%) | Aktien in Besitz |
Split Angepasst |
|---|---|---|---|
|
Apeiron Investment Group Ltd.
10% Owner -
|
0 | 0 | |
| Samuel Broder Director - [D] | 8.932 | 447 | |
|
Cambrian BioPharma Inc
10% Owner -
|
130.142 | 130.142 | |
| John Celebi PRESIDENT AND CEO, Director - [D] [O] | 105.862 | 5.293 | |
| Erin Colgan CHIEF FINANCIAL OFFICER - [O] | 67.462 | 3.373 | |
| Jessie English Director - [D] | 8.932 | 447 | |
| Patrick Stephen Gallagher Chief Business Officer - [O] | 34.130 | 1.706 |
| Insider | Durchschnittlicher Gewinn (%) | Aktien in Besitz |
Split Angepasst |
|---|---|---|---|
| Christopher Gerry President & PEO - [O] | 1.574 | 1.574 | |
|
H&s Investments I Lp
10% Owner -
|
4.425.998 | 221.300 | |
|
H&s Ventures Llc
10% Owner -
|
4.425.998 | 221.300 | |
| Bob Holmen Director - [D] | 25.598 | 1.280 | |
| Kristian Humer Director - [D] | 8.932 | 447 | |
|
Millennium Management Llc
10% Owner -
|
147.731 | 147.731 | |
|
James Peyer
10% Owner -
|
130.142 | 130.142 |
| Insider | Durchschnittlicher Gewinn (%) | Aktien in Besitz |
Split Angepasst |
|---|---|---|---|
| Robert Hamilton Pierce Chief R&D Officer - [O] | 21.000 | 1.050 | |
| Thomas G Ricks Director - [D] | 343.863 | 17.193 | |
| William R Ringo Director - [D] | 23.399 | 1.170 | |
|
Henry Samueli
10% Owner -
|
4.425.998 | 221.300 | |
|
Susan Samueli
10% Owner -
|
4.425.998 | 221.300 | |
|
Michael Schulman
10% Owner -
|
4.425.998 | 221.300 | |
| Deneen Vojta Director - [D] | 8.932 | 447 | |
| der Horst Edward van CHIEF SCIENTIFIC OFFICER - [O] | 59.794 | 2.990 |
Report errors via our new Insider Auditing Tool
Erfolgsbilanz der Insiderkäufe - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in SNSE / Sensei Biotherapeutics, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch .
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
Bereinigter Preis ist der splitbereinigte Preis. Bereinigte Aktien sind die um den Split bereinigten Aktien.
Erfolgsbilanz von Insiderverkäufen - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in SNSE / Sensei Biotherapeutics, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch .
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
Bereinigter Preis ist der splitbereinigte Preis. Bereinigte Aktien sind die um den Split bereinigten Aktien.
Transaktionshistorie
Klicken Sie auf das Link-Symbol, um den vollständigen Transaktionsverlauf anzuzeigen. Transaktionen, die im Rahmen eines automatischen Handelsplans 10b5-1 gemeldet werden, sind in der Spalte 10b-5 mit einem X gekennzeichnet.
| Datei Datum |
Handel Datum |
Form | Insider | Ticker | Wertpapier-Titel | Code | Direkt | Ausführung Preis |
Einheit Preis |
Eimheiten Verändert |
Wert Geändert (1K) |
Verbleibende Optionen |
Verbleibende Aktien |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-01 | 2026-06-01 | 4 | Peyer James | SNSE | Common Stock | D | 21,1400 | -476 | -10 | 130.142 | ||||
| 2026-06-01 | 2026-06-01 | 4 | Peyer James | SNSE | Common Stock | D | 20,0000 | -24.524 | -490 | 130.618 | ||||
| 2026-06-01 | 2026-06-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 21,1400 | -476 | -10 | 130.142 | ||||
| 2026-06-01 | 2026-06-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 20,0000 | -24.524 | -490 | 130.618 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 33,3800 | -1.108 | -37 | 133.986 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 32,2467 | -300 | -10 | 133.986 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,3843 | -4.423 | -139 | 133.986 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 29,7146 | -205 | -6 | 133.986 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 28,9417 | -2.115 | -61 | 133.986 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 33,3800 | 1.108 | 37 | 133.986 | ||||
| 2026-05-15 | 2026-04-06 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,9628 | -45 | -1 | 141.029 | ||||
| 2026-05-15 | 2026-04-06 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,0227 | -1.214 | -38 | 141.029 | ||||
| 2026-05-15 | 2026-04-06 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,0200 | 1.104 | 34 | 141.029 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 34,8007 | -1.134 | -39 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 33,3470 | -374 | -12 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 32,6041 | -1.794 | -58 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,7510 | -1.265 | -40 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 30,8638 | -3.099 | -96 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 35,5472 | 701 | 25 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 34,7524 | 1.276 | 44 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 33,4704 | 26 | 1 | 144.974 | ||||
| 2026-05-15 | 3 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 127.095 | ||||||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,6800 | -370 | -10 | 145.678 | ||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 25,8501 | -518 | -13 | 145.678 | ||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,6800 | 370 | 10 | 145.678 | ||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 26,7000 | 1.176 | 31 | 145.678 | ||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 25,9900 | 4.995 | 130 | 145.678 | ||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 25,0784 | 2.992 | 75 | 145.678 | ||||
| 2026-05-15 | 2026-03-27 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,3690 | -36 | -1 | 142.360 | ||||
| 2026-05-15 | 2026-03-27 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 26,7652 | -469 | -13 | 142.360 | ||||
| 2026-05-15 | 2026-03-27 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 28,1301 | 294 | 8 | 142.360 | ||||
| 2026-05-15 | 2026-03-27 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,2826 | 4.384 | 120 | 142.360 | ||||
| 2026-05-15 | 2026-03-27 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 26,2933 | 10.643 | 280 | 142.360 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 28,6882 | -1.274 | -37 | 131.370 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 26,8797 | -583 | -16 | 131.370 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 29,9788 | 1.025 | 31 | 131.370 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 28,8539 | 2.601 | 75 | 131.370 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,9467 | 1.327 | 37 | 131.370 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,2267 | 778 | 21 | 131.370 | ||||
| 2026-05-15 | 2026-04-01 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 34,7464 | -46 | -2 | 147.731 | ||||
| 2026-05-15 | 2026-04-01 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,5200 | -1.104 | -35 | 147.731 | ||||
| 2026-05-15 | 2026-04-01 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 35,4554 | 3.401 | 121 | 147.731 | ||||
| 2026-05-15 | 2026-04-01 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 34,5863 | 1.613 | 56 | 147.731 | ||||
| 2026-05-15 | 2026-04-01 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,5309 | 1.161 | 37 | 147.731 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,5200 | -87 | -3 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 28,4050 | -5 | -0 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,1147 | -57 | -2 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 25,1676 | -1.251 | -31 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 24,2843 | -191 | -5 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 32,5962 | 411 | 13 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,4512 | 1.957 | 62 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 30,4754 | 186 | 6 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,7838 | 17 | 0 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 26,7259 | 1.048 | 28 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 25,3209 | 1.770 | 45 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 24,6857 | 616 | 15 | 146.657 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 7,9200 | -446 | -4 | 155.142 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 8,0400 | -395 | -3 | 155.588 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 6,4000 | 395 | 3 | 155.983 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 7,9500 | -2.666 | -21 | 155.588 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 8,5900 | -3.105 | -27 | 158.254 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Peyer James | SNSE | Common Stock | I | 7,9200 | -446 | -4 | 155.142 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Peyer James | SNSE | Common Stock | I | 8,0400 | -395 | -3 | 155.588 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Peyer James | SNSE | Common Stock | I | 6,4000 | 395 | 3 | 155.983 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Peyer James | SNSE | Common Stock | I | 7,9500 | -2.666 | -21 | 155.588 | ||||
| 2025-12-10 | 2025-12-08 | 4 | Peyer James | SNSE | Common Stock | I | 8,5900 | -3.105 | -27 | 158.254 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 13,1600 | -42 | -1 | 161.359 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12,2900 | -1.745 | -21 | 161.401 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 11,4000 | -14.508 | -165 | 163.146 | ||||
| 2025-12-08 | 2025-12-04 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 9,0600 | -5.000 | -45 | 177.654 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Peyer James | SNSE | Common Stock | I | 13,1600 | -42 | -1 | 161.359 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Peyer James | SNSE | Common Stock | I | 12,2900 | -1.745 | -21 | 161.401 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Peyer James | SNSE | Common Stock | I | 11,4000 | -14.508 | -165 | 163.146 | ||||
| 2025-12-08 | 2025-12-04 | 4 | Peyer James | SNSE | Common Stock | I | 9,0600 | -5.000 | -45 | 177.654 | ||||
| 2025-11-24 | 3 | Gerry Christopher | SNSE | Common Stock | D | 1.574 | ||||||||
| 2025-02-26 | 2025-02-19 | 4 | Celebi John | SNSE | Common Stock | D | 0,4760 | -5.558 | -3 | 105.862 | ||||
| 2025-02-26 | 2025-02-19 | 4 | van der Horst Edward | SNSE | Common Stock | D | 0,4760 | -2.276 | -1 | 59.794 | ||||
| 2024-02-16 | 2024-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 0,7900 | -2.843 | -2 | 56.070 | ||||
| 2024-02-16 | 2024-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 0,7900 | -5.891 | -5 | 105.420 | ||||
| 2024-02-16 | 2024-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 0,7900 | -3.627 | -3 | 67.462 | ||||
| 2023-09-13 | 2023-09-11 | 4 | Celebi John | SNSE | Common Stock | D | 0,8500 | 500 | 0 | 111.311 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 1,5000 | -9.383 | -14 | 34.130 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 1,5000 | -20.492 | -31 | 110.811 | ||||
| 2023-09-11 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 1,5000 | -9.525 | -14 | 52.913 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 1,5000 | -10.943 | -16 | 68.089 | ||||
| 2023-08-02 | 2023-07-31 | 4 | Peyer James | SNSE | Common Stock | I | 1,2600 | -1.587.302 | -2.000 | 3.653.120 | ||||
| 2023-08-02 | 2023-07-31 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 1,2600 | -1.587.302 | -2.000 | 3.653.120 | ||||
| 2023-07-12 | 2023-07-10 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 4.466 | 23.399 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | D | 4.466 | 8.932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Broder Samuel | SNSE | Common Stock | D | 4.466 | 8.932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Humer Kristian | SNSE | Common Stock | D | 4.466 | 8.932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | English Jessie | SNSE | Common Stock | D | 4.466 | 8.932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Holmen Bob | SNSE | Common Stock | D | 4.466 | 25.598 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Vojta Deneen | SNSE | Common Stock | D | 4.466 | 8.932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Peyer James | SNSE | Common Stock | I | 4.466 | 5.240.422 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.466 | 5.240.422 | ||||||
| 2023-06-02 | 2023-06-01 | 4 | Apeiron Investment Group Ltd. By Presight Sensei Co-Invest Fund, L.P. | SNSE | Common Stock | I | 1,5800 | -955.738 | -1.510 | 0 | ||||
| 2023-06-02 | 2023-06-01 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1,5800 | -2.485.923 | -3.928 | 0 | ||||
| 2023-03-29 | 2023-02-15 | 4/A | Gallagher Patrick Stephen | SNSE | Common Stock | D | 14.200 | 43.513 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Gallagher Patrick Stephen | SNSE | Common Stock | D | 29.313 | 29.313 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Celebi John | SNSE | Common Stock | D | 21.300 | 131.303 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Celebi John | SNSE | Common Stock | D | 51.893 | 110.003 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Colgan Erin | SNSE | Common Stock | D | 21.300 | 79.032 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Colgan Erin | SNSE | Common Stock | D | 30.046 | 57.732 | ||||||
| 2023-03-07 | 2022-06-10 | 4/A | Cambrian BioPharma Inc | SNSE | Restricted Stock Unit Grant | D | 4.466 | 5.235.956 | ||||||
| 2023-02-27 | 2023-02-23 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1,6023 | 1.100 | 2 | 2.485.923 | ||||
| 2023-02-27 | 2023-02-23 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1,6150 | 1.100 | 2 | 2.484.823 | ||||
| 2023-02-17 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 21.300 | 127.307 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 51.893 | 106.007 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 14.200 | 43.515 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 29.313 | 29.313 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 21.300 | 73.032 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 30.046 | 51.732 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 17.700 | 62.438 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 23.565 | 44.738 | ||||||
| 2022-12-16 | 3 | van der Horst Edward | SNSE | Common Stock | D | 21.173 | ||||||||
| 2022-08-01 | 2022-06-10 | 4/A | Peyer James | SNSE | Restricted Stock Unit Grant | I | 4.466 | 5.235.956 | ||||||
| 2022-08-01 | 3/A | Peyer James | SNSE | Common Stock | I | 2.282.827 | ||||||||
| 2022-07-20 | 3 | Presight Co-Invest Management, L.L.C. By Presight Sensei Co-Invest Fund, L.P. | SNSE | Common Stock | I | 955.738 | ||||||||
| 2022-07-20 | 3 | Presight Co-Invest Management, L.L.C. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 2.483.723 | ||||||||
| 2022-06-14 | 2022-06-10 | 4 | Cambrian BioPharma Inc | SNSE | Restricted Stock Unit Grant | D | 4.466 | 5.235.954 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Peyer James | SNSE | Restricted Stock Unit Grant | I | 4.466 | 5.235.954 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Humer Kristian | SNSE | Common Stock | D | 4.466 | 4.466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Vojta Deneen | SNSE | Common Stock | D | 4.466 | 4.466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | D | 4.466 | 4.466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | English Jessie | SNSE | Common Stock | D | 4.466 | 4.466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Holmen Bob | SNSE | Common Stock | D | 4.466 | 21.132 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Broder Samuel | SNSE | Common Stock | D | 4.466 | 4.466 | ||||||
| 2022-06-10 | 2022-03-02 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,2000 | 1.203 | 4 | 5.231.488 | ||||
| 2022-06-10 | 2022-03-02 | 4/A | Peyer James | SNSE | Common Stock | I | 3,2000 | 1.203 | 4 | 5.231.488 | ||||
| 2022-04-21 | 2021-03-23 | 4/A | Peyer James | SNSE | Common Stock | I | 14,3400 | 9.500 | 136 | 4.798.293 | ||||
| 2022-04-21 | 2021-02-18 | 4/A | Peyer James | SNSE | Common Stock | I | 19,7500 | 752 | 15 | 4.690.905 | ||||
| 2022-04-21 | 2021-03-23 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,3400 | 9.500 | 136 | 4.798.293 | ||||
| 2022-04-21 | 2021-02-18 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19,7500 | 752 | 15 | 4.690.905 | ||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Stock Option (Right to Buy) | D | 3,08 | 29.100 | 29.100 | |||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 10.000 | 18.933 | ||||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 8.933 | 8.933 | ||||||
| 2022-03-02 | 2022-03-02 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,2000 | 1.203 | 4 | 5.231.989 | ||||
| 2022-03-02 | 2022-03-02 | 4 | Peyer James | SNSE | Common Stock | I | 3,2000 | 1.203 | 4 | 5.231.989 | ||||
| 2022-03-01 | 2022-03-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,6000 | 2.458 | 9 | 5.230.786 | ||||
| 2022-03-01 | 2022-02-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,6000 | 42 | 0 | 5.228.328 | ||||
| 2022-03-01 | 2022-03-01 | 4 | Peyer James | SNSE | Common Stock | I | 3,6000 | 2.458 | 9 | 5.230.786 | ||||
| 2022-03-01 | 2022-02-28 | 4 | Peyer James | SNSE | Common Stock | I | 3,6000 | 42 | 0 | 5.228.328 | ||||
| 2022-02-28 | 2022-02-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,6500 | 2.500 | 9 | 5.228.286 | ||||
| 2022-02-28 | 2022-02-25 | 4 | Peyer James | SNSE | Common Stock | I | 3,6500 | 2.500 | 9 | 5.228.286 | ||||
| 2022-02-24 | 2022-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,6300 | 15.000 | 54 | 5.225.786 | ||||
| 2022-02-24 | 2022-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,8000 | 2.500 | 10 | 5.210.786 | ||||
| 2022-02-24 | 2022-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 3,6300 | 15.000 | 54 | 5.225.786 | ||||
| 2022-02-24 | 2022-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 3,8000 | 2.500 | 10 | 5.210.786 | ||||
| 2022-02-22 | 2022-02-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,9700 | 15.000 | 60 | 5.208.286 | ||||
| 2022-02-22 | 2022-02-17 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,1700 | 4.949 | 21 | 5.193.286 | ||||
| 2022-02-22 | 2022-02-18 | 4 | Peyer James | SNSE | Common Stock | I | 3,9700 | 15.000 | 60 | 5.208.286 | ||||
| 2022-02-22 | 2022-02-17 | 4 | Peyer James | SNSE | Common Stock | I | 4,1700 | 4.949 | 21 | 5.193.286 | ||||
| 2022-02-17 | 2022-02-15 | 4 | Pierce Robert Hamilton | SNSE | Stock Option (Right to Buy) | D | 4,30 | 62.000 | 62.000 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Pierce Robert Hamilton | SNSE | Common Stock | D | 21.000 | 21.000 | ||||||
| 2022-02-17 | 2022-02-15 | 4 | Colgan Erin | SNSE | Stock Option (Right to Buy) | D | 4,30 | 62.000 | 62.000 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 21.000 | 21.686 | ||||||
| 2022-02-17 | 2022-02-15 | 4 | Celebi John | SNSE | Stock Option (Right to Buy) | D | 4,30 | 161.600 | 161.600 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 53.900 | 54.114 | ||||||
| 2022-02-16 | 2022-02-16 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,2500 | 2.551 | 11 | 5.188.337 | ||||
| 2022-02-16 | 2022-02-14 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,1800 | 10.000 | 42 | 5.185.786 | ||||
| 2022-02-16 | 2022-02-16 | 4 | Peyer James | SNSE | Common Stock | D | 4,2500 | 2.551 | 11 | 5.188.337 | ||||
| 2022-02-16 | 2022-02-14 | 4 | Peyer James | SNSE | Common Stock | I | 4,1800 | 10.000 | 42 | 5.185.786 | ||||
| 2022-02-14 | 2022-02-11 | 4 | Peyer James | SNSE | Common Stock | I | 4,4000 | 12.500 | 55 | 5.175.786 | ||||
| 2022-02-14 | 2022-02-10 | 4 | Peyer James | SNSE | Common Stock | I | 4,5800 | 5.000 | 23 | 5.163.286 | ||||
| 2022-02-14 | 2022-02-11 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,4000 | 12.500 | 55 | 5.175.786 | ||||
| 2022-02-14 | 2022-02-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,5800 | 5.000 | 23 | 5.163.286 | ||||
| 2022-02-08 | 2022-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,3300 | 10.000 | 43 | 5.158.286 | ||||
| 2022-02-08 | 2022-02-04 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,4500 | 2.500 | 11 | 5.148.286 | ||||
| 2022-02-08 | 2022-02-03 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,6500 | 17.500 | 81 | 5.145.786 | ||||
| 2022-02-08 | 2022-02-08 | 4 | Peyer James | SNSE | Common Stock | I | 4,3300 | 10.000 | 43 | 5.158.286 | ||||
| 2022-02-08 | 2022-02-04 | 4 | Peyer James | SNSE | Common Stock | I | 4,4500 | 2.500 | 11 | 5.148.286 | ||||
| 2022-02-08 | 2022-02-03 | 4 | Peyer James | SNSE | Common Stock | I | 4,6500 | 17.500 | 81 | 5.145.786 | ||||
| 2022-01-31 | 2022-01-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,2200 | 8.900 | 38 | 5.128.286 | ||||
| 2022-01-31 | 2022-01-27 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,3100 | 6.100 | 26 | 5.119.386 | ||||
| 2022-01-31 | 2022-01-28 | 4 | Peyer James | SNSE | Common Stock | I | 4,2200 | 8.900 | 38 | 5.128.286 | ||||
| 2022-01-31 | 2022-01-27 | 4 | Peyer James | SNSE | Common Stock | I | 4,3100 | 6.100 | 26 | 5.119.386 | ||||
| 2022-01-27 | 2022-01-26 | 4 | Peyer James | SNSE | Common Stock | I | 4,6200 | 29.900 | 138 | 5.113.286 | ||||
| 2022-01-27 | 2022-01-25 | 4 | Peyer James | SNSE | Common Stock | I | 4,8600 | 20.100 | 98 | 5.083.386 | ||||
| 2022-01-27 | 2022-01-26 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,6200 | 29.900 | 138 | 5.113.286 | ||||
| 2022-01-27 | 2022-01-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,8600 | 20.100 | 98 | 5.083.386 | ||||
| 2022-01-25 | 2022-01-24 | 4 | Peyer James | SNSE | Common Stock | I | 4,6900 | 22.707 | 106 | 5.063.286 | ||||
| 2022-01-25 | 2022-01-21 | 4 | Peyer James | SNSE | Common Stock | I | 4,9400 | 24.703 | 122 | 5.040.579 | ||||
| 2022-01-25 | 2022-01-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,6900 | 22.707 | 106 | 5.063.286 | ||||
| 2022-01-25 | 2022-01-21 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,9400 | 24.703 | 122 | 5.040.579 | ||||
| 2022-01-21 | 2022-01-20 | 4 | Peyer James | SNSE | Common Stock | I | 5,1700 | 20.000 | 103 | 5.015.876 | ||||
| 2022-01-21 | 2022-01-19 | 4 | Peyer James | SNSE | Common Stock | I | 4,9700 | 10.244 | 51 | 4.995.876 | ||||
| 2022-01-21 | 2022-01-20 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,1700 | 20.000 | 103 | 5.015.876 | ||||
| 2022-01-21 | 2022-01-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,9700 | 10.244 | 51 | 4.995.876 | ||||
| 2022-01-20 | 2022-01-18 | 4 | Peyer James | SNSE | Common Stock | I | 5,0800 | 10.000 | 51 | 4.985.632 | ||||
| 2022-01-20 | 2022-01-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,0800 | 10.000 | 51 | 4.985.632 | ||||
| 2022-01-18 | 2022-01-14 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,9900 | 6.219 | 31 | 4.975.632 | ||||
| 2022-01-18 | 2022-01-13 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,1300 | 19.953 | 102 | 4.969.413 | ||||
| 2022-01-18 | 2022-01-14 | 4 | Peyer James | SNSE | Common Stock | I | 4,9900 | 6.219 | 31 | 4.975.632 | ||||
| 2022-01-18 | 2022-01-13 | 4 | Peyer James | SNSE | Common Stock | I | 5,1300 | 19.953 | 102 | 4.969.413 | ||||
| 2022-01-13 | 2022-01-12 | 4 | Peyer James | SNSE | Common Stock | I | 5,2200 | 9.202 | 48 | 4.949.460 | ||||
| 2022-01-13 | 2022-01-11 | 4 | Peyer James | SNSE | Common Stock | I | 5,1800 | 10.845 | 56 | 4.940.258 | ||||
| 2022-01-13 | 2022-01-12 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2200 | 9.202 | 48 | 4.949.460 | ||||
| 2022-01-13 | 2022-01-11 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,1800 | 10.845 | 56 | 4.940.258 | ||||
| 2022-01-11 | 2022-01-10 | 4 | Peyer James | SNSE | Common Stock | I | 5,2800 | 10.000 | 53 | 4.929.413 | ||||
| 2022-01-11 | 2022-01-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2800 | 10.000 | 53 | 4.929.413 | ||||
| 2022-01-03 | 2021-12-30 | 4 | Peyer James | SNSE | Common Stock | I | 4,8500 | 1.127 | 5 | 4.919.413 | ||||
| 2022-01-03 | 2021-12-30 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,8500 | 1.127 | 5 | 4.919.413 | ||||
| 2021-12-30 | 2021-12-29 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,9800 | 69.000 | 344 | 4.918.286 | ||||
| 2021-12-30 | 2021-12-29 | 4 | Peyer James | SNSE | Common Stock | I | 4,9800 | 69.000 | 344 | 4.918.286 | ||||
| 2021-12-29 | 2021-12-28 | 4 | Peyer James | SNSE | Common Stock | I | 5,2800 | 11.288 | 60 | 4.849.286 | ||||
| 2021-12-29 | 2021-12-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2800 | 11.288 | 60 | 4.849.286 | ||||
| 2021-12-27 | 2021-12-27 | 4 | Peyer James | SNSE | Common Stock | I | 5,3000 | 3.712 | 20 | 4.837.998 | ||||
| 2021-12-27 | 2021-12-27 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,3000 | 3.712 | 20 | 4.837.998 | ||||
| 2021-12-23 | 2021-12-23 | 4 | Peyer James | SNSE | Common Stock | I | 5,2700 | 11.000 | 58 | 4.834.286 | ||||
| 2021-12-23 | 2021-12-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2700 | 11.000 | 58 | 4.834.286 | ||||
| 2021-12-21 | 2021-12-17 | 4 | Peyer James | SNSE | Common Stock | I | 5,2900 | 117 | 1 | 4.823.286 | ||||
| 2021-12-21 | 2021-12-17 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2900 | 117 | 1 | 4.823.286 | ||||
| 2021-12-20 | 2021-12-16 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2500 | 10.925 | 57 | 4.823.169 | ||||
| 2021-12-20 | 2021-12-16 | 4 | Peyer James | SNSE | Common Stock | I | 5,2500 | 10.925 | 57 | 4.823.169 | ||||
| 2021-12-13 | 2021-12-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 5,8600 | 20.000 | 117 | 341.769 | ||||
| 2021-12-13 | 2021-12-09 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 6,6200 | 20.000 | 132 | 321.769 | ||||
| 2021-08-12 | 2021-08-11 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7,3436 | -16.030 | -118 | 0 | ||||
| 2021-08-10 | 2021-08-10 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7,1289 | -66.350 | -473 | 16.030 | ||||
| 2021-08-10 | 2021-08-09 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7,0603 | -6.982 | -49 | 82.380 | ||||
| 2021-08-10 | 2021-08-06 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7,1127 | -6.460 | -46 | 89.362 | ||||
| 2021-08-10 | 3/A | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 95.822 | ||||||||
| 2021-08-02 | 2021-07-30 | 4 | Humer Kristian | SNSE | Stock Option (Right to Buy) | D | 7,89 | 16.667 | 16.667 | |||||
| 2021-05-06 | 2021-05-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12,0000 | 350 | 4 | 4.812.244 | ||||
| 2021-05-06 | 2021-05-05 | 4 | Peyer James | SNSE | Common Stock | I | 12,0000 | 350 | 4 | 4.812.244 | ||||
| 2021-04-21 | 2021-04-20 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12,7700 | 385 | 5 | 4.811.894 | ||||
| 2021-04-21 | 2021-04-20 | 4 | Peyer James | SNSE | Common Stock | I | 12,7700 | 385 | 5 | 4.811.894 | ||||
| 2021-04-20 | 2021-04-19 | 4 | Peyer James | SNSE | Common Stock | I | 13,3800 | 1.965 | 26 | 4.811.509 | ||||
| 2021-04-20 | 2021-04-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 13,3800 | 1.965 | 26 | 4.811.509 | ||||
| 2021-04-14 | 2021-04-13 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,0000 | 2.000 | 28 | 4.809.544 | ||||
| 2021-04-14 | 2021-04-13 | 4 | Peyer James | SNSE | Common Stock | I | 14,0000 | 2.000 | 28 | 4.809.544 | ||||
| 2021-04-08 | 2021-04-07 | 4 | Peyer James | SNSE | Common Stock | I | 14,0000 | 2.000 | 28 | 4.807.544 | ||||
| 2021-04-08 | 2021-04-07 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,0000 | 2.000 | 28 | 4.807.544 | ||||
| 2021-04-05 | 2021-04-01 | 4 | English Jessie | SNSE | Stock Option (Right to Buy) | D | 14,42 | 16.667 | 16.667 | |||||
| 2021-04-02 | 2021-04-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,0000 | 1.000 | 14 | 4.805.544 | ||||
| 2021-04-02 | 2021-04-01 | 4 | Peyer James | SNSE | Common Stock | I | 14,0000 | 1.000 | 14 | 4.805.544 | ||||
| 2021-03-31 | 2021-03-30 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12,0000 | 2.000 | 24 | 4.804.544 | ||||
| 2021-03-31 | 2021-03-30 | 4 | Peyer James | SNSE | Common Stock | I | 12,0000 | 2.000 | 24 | 4.804.544 | ||||
| 2021-03-25 | 2021-03-24 | 4 | Peyer James | SNSE | Common Stock | I | 14,1200 | 3.750 | 53 | 4.802.544 | ||||
| 2021-03-25 | 2021-03-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,1200 | 3.750 | 53 | 4.802.544 | ||||
| 2021-03-24 | 2021-03-23 | 4 | Peyer James | SNSE | Common Stock | I | 14,3400 | 10.000 | 143 | 4.798.794 | ||||
| 2021-03-24 | 2021-03-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,3400 | 10.000 | 143 | 4.798.794 | ||||
| 2021-03-23 | 2021-03-22 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15,0200 | 2.183 | 33 | 4.788.794 | ||||
| 2021-03-23 | 2021-03-22 | 4 | Peyer James | SNSE | Common Stock | I | 15,0200 | 2.183 | 33 | 4.788.794 | ||||
| 2021-03-19 | 2021-03-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15,2500 | 817 | 12 | 4.786.611 | ||||
| 2021-03-19 | 2021-03-18 | 4 | Peyer James | SNSE | Common Stock | I | 15,2500 | 817 | 12 | 4.786.611 | ||||
| 2021-03-10 | 2021-03-08 | 4 | Peyer James | SNSE | Common Stock | I | 15,2490 | 1.000 | 15 | 4.785.794 | ||||
| 2021-03-10 | 2021-03-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15,2490 | 1.000 | 15 | 4.785.794 | ||||
| 2021-03-08 | 2021-03-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 13,7500 | 8.000 | 110 | 4.784.794 | ||||
| 2021-03-08 | 2021-03-05 | 4 | Peyer James | SNSE | Common Stock | I | 13,7500 | 8.000 | 110 | 4.784.794 | ||||
| 2021-03-05 | 2021-03-04 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,1250 | 2.000 | 28 | 4.776.794 | ||||
| 2021-03-05 | 2021-03-03 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15,8500 | 3.000 | 48 | 4.774.794 | ||||
| 2021-03-05 | 2021-03-04 | 4 | Peyer James | SNSE | Common Stock | I | 14,1250 | 2.000 | 28 | 4.776.794 | ||||
| 2021-03-05 | 2021-03-03 | 4 | Peyer James | SNSE | Common Stock | I | 15,8500 | 3.000 | 48 | 4.774.794 | ||||
| 2021-03-03 | 2021-03-02 | 4 | Peyer James | SNSE | Common Stock | I | 16,2500 | 3.000 | 49 | 4.771.794 | ||||
| 2021-03-03 | 2021-03-02 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16,2500 | 3.000 | 49 | 4.771.794 | ||||
| 2021-03-02 | 2021-02-26 | 4 | Peyer James | SNSE | Common Stock | I | 16,2500 | 5.000 | 81 | 4.768.794 | ||||
| 2021-03-02 | 2021-02-26 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16,2500 | 5.000 | 81 | 4.768.794 | ||||
| 2021-02-26 | 2021-02-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15,7900 | 12.000 | 189 | 4.763.794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18,4200 | 900 | 17 | 4.751.794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16,8400 | 18.100 | 305 | 4.750.894 | ||||
| 2021-02-26 | 2021-02-25 | 4 | Peyer James | SNSE | Common Stock | I | 15,7900 | 12.000 | 189 | 4.763.794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 18,4200 | 900 | 17 | 4.751.794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 16,8400 | 18.100 | 305 | 4.750.894 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18,1000 | 14.300 | 259 | 4.732.794 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 17,0400 | 6.000 | 102 | 4.718.494 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 18,1000 | 14.300 | 259 | 4.732.794 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 17,0400 | 6.000 | 102 | 4.718.494 | ||||
| 2021-02-24 | 2021-02-22 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18,8800 | 9.802 | 185 | 4.712.494 | ||||
| 2021-02-24 | 2021-02-22 | 4 | Peyer James | SNSE | Common Stock | I | 18,8800 | 9.802 | 185 | 4.712.494 | ||||
| 2021-02-23 | 2021-02-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19,7700 | 11.786 | 233 | 4.702.692 | ||||
| 2021-02-23 | 2021-02-19 | 4 | Peyer James | SNSE | Common Stock | I | 19,7700 | 11.786 | 233 | 4.702.692 | ||||
| 2021-02-19 | 2021-02-18 | 4 | Peyer James | SNSE | Common Stock | I | 19,7500 | 753 | 15 | 4.690.906 | ||||
| 2021-02-19 | 2021-02-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19,7500 | 753 | 15 | 4.690.906 | ||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Series BB Preferred Convertible Stock | I | -3.037.849 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Series AA Preferred Convertible Stock | I | -11.447.156 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 301.769 | 301.769 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James See footnotes | SNSE | Series BB Preferred Convertible Stock | I | -4.821.996 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James | SNSE | Series AA Preferred Convertible Stock | I | -110.729.827 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James | SNSE | Common Stock | I | 2.407.328 | 4.690.153 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | H&S INVESTMENTS I LP | SNSE | Series AA Convertible Preferred Stock | D | -209.368.245 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | H&S INVESTMENTS I LP | SNSE | Common Stock | D | 4.361.835 | 4.425.998 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Series BB Preferred Convertible Stock | D | -4.821.996 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Series AA Preferred Convertible Stock | D | -110.729.827 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 2.407.328 | 4.690.153 | ||||||
| 2021-02-05 | 2021-02-03 | 4 | Vojta Deneen | SNSE | Stock Option (Right to Buy) | D | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | RICKS THOMAS G | SNSE | Stock Option (Right to Buy) | D | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Holmen Bob | SNSE | Stock Option (Right to Buy) | D | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Peyer James | SNSE | Stock Option (Right to Buy) | I | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Fjaellskog Marie-Louise | SNSE | Stock Option (Right to Buy) | D | 19,00 | 79.166 | 79.166 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Hoey Anupama | SNSE | Stock Option (Right to Buy) | D | 19,00 | 83.333 | 83.333 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Colgan Erin | SNSE | Stock Option (Right to Buy) | D | 19,00 | 52.083 | 52.083 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Celebi John | SNSE | Stock Option (Right to Buy) | D | 19,00 | 416.666 | 416.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Broder Samuel | SNSE | Stock Option (Right to Buy) | D | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Cambrian BioPharma Inc | SNSE | Stock Option (Right to Buy) | D | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-03 | 3 | Pierce Robert Hamilton | SNSE | Common Stock | D | 73.463 | ||||||||
| 2021-02-03 | 3 | Holmen Bob | SNSE | Common Stock | D | 16.666 | ||||||||
| 2021-02-03 | 3 | Peyer James | SNSE | Common Stock | I | 2.282.825 | ||||||||
| 2021-02-03 | 3 | SAMUELI SUSAN | SNSE | Common Stock | D | 64.163 | ||||||||
| 2021-02-03 | 3 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 2.282.825 |
P
Offener Markt oder privater Kauf von nicht-derivativen oder derivativen Wertpapieren
S
Freiverkauf oder privater Verkauf von nicht-derivativen oder derivativen Wertpapieren
A
Gewährung, Vergabe oder sonstiger Erwerb von Wertpapieren des Unternehmens (z. B. eine Option)
C
Umwandlung von Derivaten
D
Verkauf oder Rückübertragung von Wertpapieren an das Unternehmen
F
Zahlung des Ausübungspreises oder der Steuerschuld mit einem Teil der vom Unternehmen erhaltenen Wertpapiere
G
Schenkung von Wertpapieren durch oder an den Insider
K
Aktien-Swaps und ähnliche Absicherungstransaktionen
M
Ausübung oder Umwandlung eines vom Unternehmen erhaltenen derivativen Wertpapiers (z. B. einer Option)
V
Eine freiwillig auf Formular 4 gemeldete Transaktion
J
Sonstige (mit einer Fußnote zur Beschreibung der Transaktion)
